Seclaman Edward, Narita Diana, Anghel Andrei, Cireap Natalia, Ilina Razvan, Sirbu Ioan Ovidiu, Marian Catalin
Department of Biochemistry and Pharmacology, "Victor Babeş" University of Medicine and Pharmacy, Pta Eftimie Murgu Nr. 2, 300041, Timişoara, Romania.
Donauisar Klinikum, Institute for Laboratory Diagnostic and Transfusion Medicine, Deggendorf, Germany.
Pathol Oncol Res. 2019 Jan;25(1):233-239. doi: 10.1007/s12253-017-0343-y. Epub 2017 Oct 28.
Breast cancer continues to represent a significant public health burden despite outstanding research advances regarding the molecular mechanisms of cancer biology, biomarkers for diagnostics and prognostic and therapeutic management of this disease. The studies of micro RNAs in breast cancer have underlined their potential as biomarkers and therapeutic targets; however most of these studies are still done on largely heterogeneous whole breast tissue samples. In this pilot study we have investigated the expression of four micro RNAs (miR-21, 145, 155, 92) known to be involved in breast cancer, in homogenous cell populations collected by laser capture microdissection from breast tissue section slides. Micro RNA expression was assessed by real time PCR, and associations with clinical and pathological characteristics were also explored. Our results have confirmed previous associations of miR-21 expression with poor prognosis characteristics of breast cancers such as high stage, large and highly proliferative tumors. No statistically significant associations were found with the other micro RNAs investigated, possibly due to the small sample size of our study. Our results also suggest that miR-484 could be a suitable endogenous control for data normalization in breast tissues, these results needing further confirmation by future studies. In summary, our pilot study showed the feasibility of detecting micro RNAs expression in homogenous laser captured microdissected invasive breast cancer samples, and confirmed some of the previously reported associations with poor prognostic characteristics of breast tumors.
尽管在癌症生物学分子机制、该疾病诊断及预后和治疗管理的生物标志物方面取得了显著的研究进展,但乳腺癌仍然是一个重大的公共卫生负担。对乳腺癌中微小RNA的研究突显了它们作为生物标志物和治疗靶点的潜力;然而,这些研究大多仍在很大程度上异质性的全乳腺组织样本上进行。在这项初步研究中,我们调查了已知与乳腺癌相关的四种微小RNA(miR-21、145、155、92)在通过激光捕获显微切割从乳腺组织切片载玻片上收集的同质细胞群体中的表达。通过实时PCR评估微小RNA的表达,并探讨其与临床和病理特征的关联。我们的结果证实了先前关于miR-21表达与乳腺癌预后不良特征(如高分期、大且高度增殖性肿瘤)之间的关联。对于所研究的其他微小RNA,未发现具有统计学意义的关联,这可能是由于我们研究的样本量较小。我们的结果还表明,miR-484可能是乳腺组织数据标准化的合适内参,这些结果需要未来的研究进一步证实。总之,我们的初步研究表明了在同质的激光捕获显微切割浸润性乳腺癌样本中检测微小RNA表达的可行性,并证实了一些先前报道的与乳腺肿瘤预后不良特征的关联。